Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 4/20 | 0.39 |
| ▸ | JAK1 | P23458 | 9/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29838697 | 0.94 | JAK3 (0.41) | JAK3JAK1ACACBJAK2MEN1 | |
| SCHEMBL23458628 | 0.81 | ACACB (0.35) | JAK3JAK1ACACBJAK2MEN1 | |
| SCHEMBL30002876 | 0.80 | JAK1 (0.39) | JAK3JAK1ACACBJAK2MEN1 | |
| SCHEMBL18026251 | 0.76 | JAK3 (0.36) | JAK3JAK1ACACBJAK2NUDT1 | |
| SCHEMBL19714981 | 0.74 | JAK1 (0.54) | JAK3JAK1JAK2CSF1R | |
| SCHEMBL29780438 | 0.72 | JAK1 (0.35) | JAK3JAK1ACACBJAK2TYK2 | |
| SCHEMBL28849121 | 0.72 | ACACB (0.39) | JAK3JAK1ACACBJAK2MEN1 | |
| SCHEMBL19730138 | 0.71 | TDP1 (0.33) | JAK3MEN1GAAKMT2A | |
| SCHEMBL19730142 | 0.69 | NUDT1 (0.45) | JAK3JAK1JAK2NUDT1TYK2 | |
| SCHEMBL23458592 | 0.68 | MEN1 (0.32) | MEN1NPC1GAARAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230066014-A1 | SUBSTITUTED NUCLEOSIDE ANALOGS AS PRMT5 INHIBITORS | LUPIN LIMITED (IN) | 2023-03-02 | — | — | US | disclosed |
| EP-4069698-A1 | SUBSTITUTED NUCLEOSIDE ANALOGS AS PRMT5 INHIBITORS | Lupin Limited (IN) | 2022-10-12 | — | — | EP | disclosed |
| WO-2021111322-A1 | SUBSTITUTED NUCLEOSIDE ANALOGS AS PRMT5 INHIBITORS | LUPIN LIMITED (IN) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230066014-A1 | SUBSTITUTED NUCLEOSIDE ANALOGS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | JAK3 1804/4885JAK1 1564/4885ACACB 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.